Point prevalence survey of antibiotic use in French hospitals in 2009.
Details
Serval ID
serval:BIB_4F52C7C9748A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Point prevalence survey of antibiotic use in French hospitals in 2009.
Journal
The Journal of antimicrobial chemotherapy
Working group(s)
Société de pathologie infectieuse de langue française (SPILF), Observatoire national de l'épidémiologie de la résistance bactérienne aux antibiotiques (ONERBA), Surveillance de la prescription des antibiotiques (SPA) Group
Contributor(s)
Maulin L., Schmit J., Riche A., Charvier A., Delaup J.P., Benaissa M., Sollet J.P., Courant P., Bertrand X., Janvier G., Tonnelier J.M., Soler C., Macnab C., Pospisil F., Chaix V., Duluc F., Baud O., Moulin V., Costa Y., Fortineau N., Guery B., Akpabie A., Chevalier B., Combes A., Salmon D., Dumaine V., Aslangul E., Vanjak D., Kriegel I., Clavier H., Jansen C., Fiévet M.H., Roblot F., Rezqui N., Sauve C., Rapp C., Chomarat M., Vachée A., Laurans C., Alfandari S., Burgin M., Laroussinie G., Greder-Belan A.
ISSN
1460-2091 (Electronic)
ISSN-L
0305-7453
Publication state
Published
Issued date
04/2012
Peer-reviewed
Oui
Volume
67
Number
4
Pages
1020-1026
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
To evaluate the feasibility of a point prevalence survey for monitoring antibiotic use in a voluntary sample of French hospitals.
Demographic and medical data were collected for all inpatients. Additional characteristics regarding antimicrobial treatment, type of infection and microbiological results were collected only for patients receiving antimicrobials.
Among 3964 patients in 38 hospitals, 343 (8.7%) received antimicrobial prophylaxis and 1276 (32.2%) antimicrobial therapy. The duration of surgical antimicrobial prophylaxis was >1 day in 41 out of 200 (21%) of the cases. Among patients with antimicrobial therapy, 959 (75.2%) received β-lactams (including 34.8% penicillins with β-lactam inhibitors, 22.1% third-generation cephalosporins and 7.8% carbapenems) and 301 (23.6%) received fluoroquinolones (50% orally). A total of 518 (40.6%) patients were treated with more than one drug and 345 (27.2%) were treated for >7 days. Patients treated for hospital-acquired infections (39.2%) were more likely to receive combinations (47.6% versus 34.4%, P < 0.01), carbapenems (14.4% versus 2.6%, P < 0.01), glycopeptides (14.4% versus 3.7%, P < 0.01) and antifungals (17% versus 5.3%, P < 0.01) for a longer duration (7.8 versus 6 days, P < 0.01). Fifty-six patients (4.4%) were treated for >7 days and did not have any microbiological sample drawn. The time allocated for the survey represented 18.3-25.0 h for 100 patients.
The data provide directions for further interventions, such as better use of diagnostic tools, decreasing the treatment duration and the use of combinations. In addition, the survey shows that, although cumbersome, it is feasible to improve the representativeness of national data in European surveys.
Demographic and medical data were collected for all inpatients. Additional characteristics regarding antimicrobial treatment, type of infection and microbiological results were collected only for patients receiving antimicrobials.
Among 3964 patients in 38 hospitals, 343 (8.7%) received antimicrobial prophylaxis and 1276 (32.2%) antimicrobial therapy. The duration of surgical antimicrobial prophylaxis was >1 day in 41 out of 200 (21%) of the cases. Among patients with antimicrobial therapy, 959 (75.2%) received β-lactams (including 34.8% penicillins with β-lactam inhibitors, 22.1% third-generation cephalosporins and 7.8% carbapenems) and 301 (23.6%) received fluoroquinolones (50% orally). A total of 518 (40.6%) patients were treated with more than one drug and 345 (27.2%) were treated for >7 days. Patients treated for hospital-acquired infections (39.2%) were more likely to receive combinations (47.6% versus 34.4%, P < 0.01), carbapenems (14.4% versus 2.6%, P < 0.01), glycopeptides (14.4% versus 3.7%, P < 0.01) and antifungals (17% versus 5.3%, P < 0.01) for a longer duration (7.8 versus 6 days, P < 0.01). Fifty-six patients (4.4%) were treated for >7 days and did not have any microbiological sample drawn. The time allocated for the survey represented 18.3-25.0 h for 100 patients.
The data provide directions for further interventions, such as better use of diagnostic tools, decreasing the treatment duration and the use of combinations. In addition, the survey shows that, although cumbersome, it is feasible to improve the representativeness of national data in European surveys.
Keywords
Anti-Bacterial Agents/therapeutic use, Drug Utilization/statistics & numerical data, Female, France, Hospitals, Humans, Male
Pubmed
Web of science
Create date
07/07/2023 11:04
Last modification date
23/02/2024 9:47
Usage data
